China
Africa
Explore chapters and articles related to this topic
Pathology of Breast Cancer
Published in Raymond Taillefer, Iraj Khalkhali, Alan D. Waxman, Hans J. Biersack, Radionuclide Imaging of the Breast, 2021
Nonsurgical breast sampling usually results in a specimen that is significantly smaller than those obtained by traditional excisional breast biopsy. The handling of these specimens should comply with the recommended standardized guidelines specifically developed for FNAB and core biopsies [43-45].
Hypnotherapy as an Intervention in Medicine and Psychiatry
Published in Assen Alladin, Michael Heap, Claire Frederick, Hypnotherapy Explained, 2018
Assen Alladin, Michael Heap, Claire Frederick
Lang et al. (2006) conducted another similarly designed randomized controlled study on hypnosis in 236 women undergoing large-core breast biopsies. Large-core breast biopsy is known to be highly anxiety provoking (Bugbee et al., 2005) and was chosen as a representative model for outpatient surgery performed under local anesthesia only. In all three conditions – standard care, structured empathy and self-hypnosis – pain increased linearly with procedure time. Both empathy and hypnosis interventions reduced pain perception, but only hypnosis had a significant beneficial impact on anxiety: patients’ anxiety significantly heightened in the standard care group, remained unchanged in the structured empathy group, and declined significantly in the hypnosis group.
Breast Cancer
Published in Mary J. Marian, Gerard E. Mullin, Integrating Nutrition Into Practice, 2017
Cynthia A. Thomson, Deborah Straub
There are several risk factors for breast cancer including age, family history, and prior breast biopsy, especially when atypical hyperplasia is identified. Estrogen exposure is a well-established risk factor for breast cancer given its profound influence on epithelial cell growth.3 Cumulative, excessive estrogen exposure over the course of a lifetime contributes to breast cancer risk and may be a cause of this disease. Early menarche, late menopause, low parity, or delayed parity all increase a woman’s breast cancer risk.8 Greater estrogen exposure over a women’s life course can have direct genotoxic effects by increasing breast cell proliferation and random genetic errors affecting cellular differentiation and gene expression. The mechanisms of carcinogenesis include the metabolism of estrogen to mutagenic, genotoxic metabolites and the stimulation of tissue growth. These processes cause initiation, promotion, and progression of breast cancer.
Current status of biopsy markers for the breast in clinical settings
Published in Expert Review of Medical Devices, 2022
Elian A. Martin, Neeraj Chauhan, Vijian Dhevan, Elias George, Partha Laskar, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
A breast biopsy is essential for the management of suspicious breast lesions or abnormalities of the breast such as lumps and/or changes in size, shape, and skin color. About 175,000 women undergo breast-conserving surgery every year with 30% of them undergoing repeated surgery due to post-surgical margin status in the United States [1]. During assessment or screening of clinical abnormalities, often an image guided surgical or radiological biopsy procedure is involved, which removes a portion of suspect breast tissue for surgical pathologic evaluation [2]. During such procedures, placing of a breast tissue marker has become a standard practice in clinical care [3]. A breast biopsy marker or breast marker is a small device made up of surgical-grade material such as titanium or stainless steel that is placed in the area where biopsy tissue is removed by way of image guidance. The use of breast markers has become a key component of patient management [4]. The breast biopsy markers allow physicians to distinguish between tissue that has or has not been biopsied before. The placement of biopsy markers also differentiates various biopsied lesions within the tissue of the same breast. This differentiation averts physicians from performing biopsy on the same tissue twice preventing unnecessary discomfort, time, complications, and increased cost to patients [5].
The relationship between holding back from communicating about breast concerns and anxiety in the year following breast biopsy
Published in Journal of Psychosocial Oncology, 2018
Caroline S. Dorfman, Eneka Lamb, Alyssa Van Denburg, Anava A. Wren, Mary Scott Soo, Kaylee Faircloth, Vicky Gandhi, Rebecca A. Shelby
Breast cancer is the most frequently diagnosed cancer in women, with 246,660 new cases estimated in 2016 (Siegel, Miller, & Jemal, 2016). The diagnosis of breast cancer involves a breast biopsy. In the United States alone, more than one million women are expected to undergo breast biopsies in the next year (Silverstein et al., 2009). While approximately 80% of women who have a breast biopsy receive a benign result, for many, the procedure is associated with emotional distress, and in particular anxiety (Miller et al., 2013; Montgomery & McCrone; 2010). Women may report clinically elevated levels of anxiety at the time of biopsy (Miller et al., 2013; Montgomery & McCrone, 2010), and for some, pre-biopsy levels of emotional distress may remain elevated well beyond the biopsy event (Kamath et al., 2012; Witek-Janusek, Gabram, & Mathews, 2007).
Breast Care ACCESS Project
Published in Oncology Issues, 2018
Sharon Lieb Inzetta, Laura L. Musarra
Today, Summa Health is proud to offer all patients coordinated, timely access to high-quality, personalized care for any breast concern—from benign conditions to an abnormal mammogram, diagnosis, treatment, and survivorship—in a single location. New patients who are referred for a breast biopsy due to an abnormal breast finding at a diagnostic mammogram have access to specialty consults and care with a breast surgeon within 48 hours and before biopsy; remarkably, we have provided same-day surgical consults to 50 percent of the nearly 1,000 patients we see each year (Figure 1, page 37). Process improvement has allowed us to provide timely care for breast biopsies, averaging 11 total days between diagnostic mammogram and biopsy, a significant improvement from 26 days in 2014 (Figure 2, page 40). These improvements have allowed us to increase breast patient referrals for pre-biopsy surgical consult by 35 percent and reduce outmigration of diagnostic and biopsy patients (Figure 3, page 40). Here's the story of why and how we did it.